The European Medicines Agency has suspended a number of regulatory activities, including development of the new medicines web portal and work on the e-submission project, and is cutting back on meetings and conferences, to allow it to focus on addressing the implications of its forced relocation out of the UK.
The agency has also issued a stark warning that if levels of job losses resulting from its Brexit-related move to...